Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

Plain-language summary

This study investigates genetic biomarkers that could predict cancer recurrence in prostate cancer patients undergoing surgery. It included men undergoing robotic prostatectomy. It was a Phase 1 study, ongoing but not currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Active, not recruiting

Sponsor

City of Hope Medical Center

Intervention

DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymerase chain reaction, diagnostic laboratory biomarker analysis, therapeutic conventional surgery

Start date

11/26/2007

Estimated completion

7/8/2026

Countries

United States

Related genes

Locations

• Duarte, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

\- All men undergoing robotic prostatectomy or cystoprostatectomy at City of Hope will be eligible for the study

Exclusion Criteria:

\- Men who undergo neoadjuvant treatment with Androgen Deprivation Therapy (ADT) or salvage prostatectomy including those who have had brachytherapy will be excluded